In addition, Hibergene has an active research pipeline from which the company expects to release a number of tests on a yearly basis.

The tests meet a significant unmet clinical need allowing clinicians to rapidly, accurately and easily detect human infectious diseases in a near patient setting.

The company CEO is Brendan Farrell, an industry veteran, who was a founder of Trinity Biotech. The company is headquartered in Ireland and its investors include a number of institutions and private investors.